13 completed. 13 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Dermatofibrosarcoma: new trials by email Literature Review of Dermatofibrosarcoma trials Research Report on Dermatofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-02-01 | 2018-06-29 |
| Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas sunitinib malate - Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 53 | 2007-04-01 | 2016-01-20 |
| Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans imatinib mesylate - Dermatofibrosarcoma Protuberans | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 18 | 2006-05-01 | 2012-03-29 |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes imatinib mesylate - Hypereosinophilic Syndrome, Systemic Mastocytosis | Phase 2 | Completed | Novartis Pharmaceuticals | 38 | 2004-09-01 | 2017-02-23 |
| Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans imatinib mesylate, laboratory biomarker analysis - Adult Fibrosarcoma, Dermatofibrosarcoma Protuberans | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-05-01 | 2013-02-28 |
| Imatinib in Dermatofibrosarcoma Protuberans (DFSP) Imatinib (Glivec) - Dermatofibrosarcoma | Phase 1 / Phase 2 | Completed | Dermatologic Cooperative Oncology Group | 30 | 2004-01-01 | 2011-07-29 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Imatinib mesylate - Life Threatening Diseases | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2001-02-01 | 2016-11-18 |
Sarcoma (8) · Fibrosarcoma (7) · Histiocytoma, Malignant Fibrous (7) · Leiomyosarcoma (7) · Liposarcoma (7) · Neurofibrosarcoma (6) · Sarcoma, Synovial (5) · Hemangiosarcoma (4) · Osteosarcoma (4) · Rhabdomyosarcoma (4) · Chondrosarcoma (3) · Chondrosarcoma, Extraskeletal Myxoid (3) · Malignant mesenchymal tumor (3) · Sarcoma, Alveolar Soft Part (3)
Neoplasms by Histologic Type (13) · Neoplasms, Connective Tissue (13) · Neoplasms, Connective and Soft Tissue (13) · Neoplasms, Fibrous Tissue (13) · Neoplasms (11) · Neoplasms, Muscle Tissue (8) · Histiocytoma (7) · Neoplasms, Adipose Tissue (7) · Neoplasms, Nerve Tissue (7) · Fibrosarcoma (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Neurofibroma (6) · Neuromuscular Diseases (6) · Peripheral Nervous System Diseases (6)
Imatinib Mesylate (5) · Doxorubicin (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Albumin-Bound Paclitaxel (1) · Dexrazoxane (1) · HhAntag691 (1) · Ifosfamide (1) · Immune Checkpoint Inhibitors (1) · MLN 8237 (1) · Radiation (1) · Radiotherapy (1) · Razoxane (1) · Sunitinib (1) · pazopanib (1)
National Cancer Institute (NCI) (5) · Novartis Pharmaceuticals (2) · BioAtla, Inc. (1) · Celgene (1) · Dermatologic Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Sarcoma Alliance for Research through Collaboration (1) · Washington University School of Medicine (1)
United States (10) · Canada (3) · Australia (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Puerto Rico (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Aaron R Weiss (1) · Brian A Van Tine, M.D., Ph.D. (1) · Dirk Schadendorf, MD (1) · Ileana Elias, M.D. (1) · Margaret von Mehren (1) · Mark Dickson (1) · Mary L. Keohan, MD (1) · Michael Heinrich, MD (1) · Mrinal Gounder (1) · Robert Maki, MD, PhD (1) · Scott Schuetze (1) · Scott Schuetze, MD, PhD (1) · Selma Ugurel, MD (1)
PMID 19451429, PMID 19451433, PMID 27502708, PMID 31401903, PMID 32554315, PMID 32702309, PMID 32827353, PMID 34515544, PMID 37523624, PMID 38579194
P30CA008748 (2), N01CM62203 (1), N01CM62206 (1), U01CA069856 (1), U10CA031946 (1), U10CA032102 (1), U10CA098543 (1), U10CA180821 (1), U10CA180830 (1), U10CA180886 (1)